Inovio’s Voceryq receives FDA accelerated approval for RRP
Continued approval of the therapy may depend on verification of clinical benefit through a confirmatory study.
Drug Development
Dren Bio raises $350m for dibotatug clinical development
Enthorin and Rumi sign agreement for FXS therapy
Formation Bio launches $600m drug development fund
FDA grants orphan drug status to Octant’s OCT-980 for RP
Arrowhead gains UK marketing authorisation for Redemplo
Regeneron agrees to $270m extension to supply Ebola medicine in US
China’s NMPA accepts Innovent application for sintilimab combo
